Corbus Pharmaceuticals (CRBP) announced the last patient has been enrolled and completed the first clinical visit in the company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track to be completed in the summer of 2026. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Aligns With FDA on CRB-701 Registrational Path
- Corbus reports FDA alignment for CRB-701, CMO Dominic Smethurst departure
- Corbus Pharmaceuticals price target raised to $40 from $39 at Mizuho
- 3 Best Stocks to Buy Today, 4/3/2026, According to Top Analysts
- Corbus Pharmaceuticals files $300M mixed securities shelf